Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 27 Mendeley

Summary X

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 28,309 followers.

RT @FrontOncology: 📄 Don't miss this study of the safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with #BreastCance…

23 Aug 2022

Reply Repost Favourite

📄 Don't miss this study of the safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with #BreastCancer and #GynOnc cancers! 👨‍⚕️👩‍⚕️ Peitro De Placido et al Available here #OpenAccess 👉 https://t.co/XgT6F3aF4n #BCsm #GYNsm #Oncology

23 Aug 2022

Reply Repost Favourite

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study: Background Vaccines against severe acute #oncology… https://t.co/0wunD

20 Aug 2022

Reply Repost Favourite

New research: Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study: Background Vaccines against severe acute… https://t.co/g

20 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.